In a 2-year rat carcinogenicity study, intranasal administration of dihydroergotamine mesylate (0, 0.4, 0.8 or 1.6 mg/day for 13 weeks, followed by 0, 0.08, 0.24 or 0.8 mg/day for the remainder of the study) did not result in an increase in tumors
3 GLP-1s are multi-system therapies
Similarly, Pes et al
PLoS ONE 8:e81640
(3) the product prepared by the invention omits the crushing and subpackaging operation process, has low moisture content (the moisture content of the invention is controlled in a lower range, and the moisture content of the invention is less than or equal to 2.0 percent), and better solves the problems that the product is easy to absorb moisture, is easy to oxidize and decompose and is polluted by microorganisms in the crushing and subpackaging process
The useful question is not "Did I log everything?" It is "Can I see what changed after dose day, what foods felt good or bad, whether I got enough protein and water, and what I should mention to my clinician?" Food tracking on a GLP-1 is different from dieting
